JP2019501927A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501927A5
JP2019501927A5 JP2018536252A JP2018536252A JP2019501927A5 JP 2019501927 A5 JP2019501927 A5 JP 2019501927A5 JP 2018536252 A JP2018536252 A JP 2018536252A JP 2018536252 A JP2018536252 A JP 2018536252A JP 2019501927 A5 JP2019501927 A5 JP 2019501927A5
Authority
JP
Japan
Prior art keywords
hydrate
pharmaceutically acceptable
acceptable salt
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501927A (ja
JP6916185B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013100 external-priority patent/WO2017123695A1/en
Publication of JP2019501927A publication Critical patent/JP2019501927A/ja
Publication of JP2019501927A5 publication Critical patent/JP2019501927A5/ja
Application granted granted Critical
Publication of JP6916185B2 publication Critical patent/JP6916185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536252A 2016-01-13 2017-01-12 Btk阻害剤としてのイソキノロン類 Active JP6916185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662278085P 2016-01-13 2016-01-13
US62/278,085 2016-01-13
PCT/US2017/013100 WO2017123695A1 (en) 2016-01-13 2017-01-12 Isoquinolones as btk inhibitors

Publications (3)

Publication Number Publication Date
JP2019501927A JP2019501927A (ja) 2019-01-24
JP2019501927A5 true JP2019501927A5 (cg-RX-API-DMAC7.html) 2020-02-13
JP6916185B2 JP6916185B2 (ja) 2021-08-11

Family

ID=57907002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536252A Active JP6916185B2 (ja) 2016-01-13 2017-01-12 Btk阻害剤としてのイソキノロン類

Country Status (4)

Country Link
US (1) US10570118B2 (cg-RX-API-DMAC7.html)
EP (1) EP3402789B1 (cg-RX-API-DMAC7.html)
JP (1) JP6916185B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017123695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6959252B2 (ja) * 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Dub阻害剤としての1−シアノピロリジン誘導体
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
EP3972963A1 (en) * 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
BR112021023110A2 (pt) * 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115650851A (zh) * 2022-11-10 2023-01-31 无锡双启科技有限公司 一种2-氟-4-溴-6-甲基苯甲酸甲酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
ATE325608T1 (de) 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
EP1436265A4 (en) 2001-09-27 2004-12-15 Smithkline Beecham Corp CHEMICALS
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
CN101460466B (zh) 2006-04-11 2012-06-13 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的噻唑类、咪唑类和吡唑类
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CN103319488A (zh) 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂
CA2710462C (en) * 2008-02-05 2015-11-24 F. Hoffmann-La Roche Ag Pyridinones and pyridazinones
AU2009264400B2 (en) * 2008-06-24 2014-05-01 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
DK2310528T3 (da) 2008-07-29 2013-12-02 Univ Liege Genetisk markør-test til brachyspina og frugtbarhed hos kvæg
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2784647A1 (en) 2009-12-17 2011-07-14 Merck Patent Gmbh Inhibitors of sphingosine kinase
BR112012030711B1 (pt) 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
CA2834077A1 (en) * 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9458162B2 (en) 2012-01-31 2016-10-04 Nanjing Allgen Pharma Co. Ltd. Cyclic molecules as bruton's tyrosine kinase inhibitors
IN2012CH01573A (cg-RX-API-DMAC7.html) * 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
JP6348492B2 (ja) 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ(btk)阻害剤としてのヘテロ芳香族化合物
RU2015111133A (ru) * 2012-09-13 2016-11-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
KR101668574B1 (ko) 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
KR20160046917A (ko) 2013-09-03 2016-04-29 카나 바이오사이언스, 인코포레이션 신규 2,6-디아미노피리미딘 유도체
WO2015050703A1 (en) * 2013-10-04 2015-04-09 Yi Chen Inhibitors of bruton's tyrosine kinase
JP6486954B2 (ja) 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としてのピラゾール化合物
EA034561B1 (ru) 2015-12-16 2020-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний

Similar Documents

Publication Publication Date Title
JP2019501927A5 (cg-RX-API-DMAC7.html)
JP2017511357A5 (cg-RX-API-DMAC7.html)
JP2015502387A5 (cg-RX-API-DMAC7.html)
JP2015509535A5 (cg-RX-API-DMAC7.html)
JP2016540742A5 (cg-RX-API-DMAC7.html)
JP2017504635A5 (cg-RX-API-DMAC7.html)
JP2010530897A5 (cg-RX-API-DMAC7.html)
JP2010504286A5 (cg-RX-API-DMAC7.html)
JP2016034968A5 (cg-RX-API-DMAC7.html)
PH12015500294A1 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
JP2015535832A5 (cg-RX-API-DMAC7.html)
JP2006524669A5 (cg-RX-API-DMAC7.html)
JP2016520618A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2009516727A5 (cg-RX-API-DMAC7.html)
JP2009534407A5 (cg-RX-API-DMAC7.html)
JP2009534406A5 (cg-RX-API-DMAC7.html)
JP2020502268A5 (cg-RX-API-DMAC7.html)
JP2014509647A5 (cg-RX-API-DMAC7.html)
JP2018500287A5 (cg-RX-API-DMAC7.html)
JP2016529246A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
JP2020500916A5 (cg-RX-API-DMAC7.html)
JP2019532092A5 (cg-RX-API-DMAC7.html)
JP2008500999A5 (cg-RX-API-DMAC7.html)